Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis

Annals of the Rheumatic Diseases
A CalinS Fatenejad

Abstract

A double blind, randomised, placebo controlled study to evaluate the safety and efficacy of etanercept to treat adult patients with ankylosing spondylitis (AS). Adult patients with AS at 14 European sites were randomly assigned to 25 mg injections of etanercept or placebo twice weekly for 12 weeks. The primary efficacy end point was an improvement of at least 20% in patient reported symptoms, based on the multicomponent Assessments in Ankylosing Spondylitis (ASAS) response criteria (ASAS 20). Secondary end points included ASAS 50 and ASAS 70 responses and improved scores on individual components of ASAS, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), acute phase reactants, and spinal mobility tests. Safety was evaluated during scheduled visits. Of 84 patients enrolled, 45 received etanercept and 39 received placebo. Significantly more etanercept patients than placebo patients responded at the ASAS 20 level as early as week 2, and sustained differences were evident up to week 12. Significantly more etanercept patients reported ASAS 50 responses at all times and ASAS 70 responses at weeks 2, 4, and 8; reported lower composite and fatigue BASDAI scores; had lower acute phase reactant levels; and had improved spin...Continue Reading

References

Oct 1, 1991·British Journal of Rheumatology·J A GoodacreW C Dick
Nov 1, 1989·Annals of the Rheumatic Diseases·V S Ringsdal, J J Andreasen
Jul 1, 1997·British Journal of Rheumatology·J T Gran, J F Skomsvoll
Mar 13, 1999·Annals of Internal Medicine·L W MorelandM E Weinblatt
Feb 26, 2000·Arthritis Care and Research : the Official Journal of the Arthritis Health Professions Association·M M Ward
Nov 4, 2000·Expert Opinion on Investigational Drugs·R Fernandez-Botran
Nov 30, 2000·The New England Journal of Medicine·J M BathonB K Finck
Oct 20, 2001·Arthritis and Rheumatism·J H BarlowA Keat
Apr 5, 2002·Arthritis and Rheumatism·Astrid van TubergenDésirée van der Heijde
May 3, 2002·The New England Journal of Medicine·Jennifer D GormanJohn C Davis
Jun 27, 2002·Expert Opinion on Investigational Drugs·Walter P Maksymowych
Oct 31, 2002·Best Practice & Research. Clinical Rheumatology·Walter P MaksymowychJ Braun
Nov 8, 2002·Rheumatology·B RoychowdhuryR J Moots
Feb 14, 2003·The New England Journal of Medicine·Filip BaertPaul Rutgeerts
Mar 15, 2003·Rheumatic Diseases Clinics of North America·Diana FloresLuis R Espinoza
Nov 13, 2003·Arthritis and Rheumatism·John C DavisUNKNOWN Enbrel Ankylosing Spondylitis Study Group

❮ Previous
Next ❯

Citations

Jun 27, 2006·Rheumatology International·Melissa PadovanFrancesco Trotta
Jun 30, 2009·Rheumatology International·L Goh, A Samanta
Dec 6, 2005·Zeitschrift für Rheumatologie·M Rudwaleit, J Sieper
Mar 3, 2007·Clinical Rheumatology·Liisa KonttinenUNKNOWN ROB-FIN Study Group
Jul 21, 2009·Clinical Rheumatology·Rohit Aggarwal, Anand N Malaviya
May 27, 2008·Wiener medizinische Wochenschrift·Hans-Eckhard Langer
Mar 1, 2006·Reumatología clinica·UNKNOWN Comité Mexicano del Consenso de Biológicos. Colegio Mexicano de Reumatología
Aug 26, 2006·Nature Clinical Practice. Rheumatology·Cailin Henderson, John C Davis
Apr 20, 2005·Current Opinion in Rheumatology·Allen Anandarajah, Christopher T Ritchlin
Jun 16, 2005·Current Opinion in Rheumatology·Jane Zochling, Jürgen Braun
Apr 7, 2007·Current Opinion in Rheumatology·Augustine M ManadanJoel A Block
Dec 25, 2012·Annals of the Rheumatic Diseases·Irene E van der Horst-BruinsmaAndrew S Koenig
Apr 22, 2005·Annals of the Rheumatic Diseases·J C DavisW Tsuji
Aug 30, 2005·Annals of the Rheumatic Diseases·J ZochlingUNKNOWN European League Against Rheumatism
Oct 22, 2005·Annals of the Rheumatic Diseases·J Sieper, M Rudwaleit
Sep 14, 2006·Annals of the Rheumatic Diseases·D van der HeijdeUNKNOWN Etanercept Study 314 Investigators
Feb 28, 2007·Annals of the Rheumatic Diseases·Vinod ChandranDafna D Gladman
Sep 16, 2006·BMJ : British Medical Journal·Claire M McVeigh, Andrew P Cairns
Aug 2, 2008·American Journal of Respiratory and Critical Care Medicine·Ganesh RaghuSaeed Fatenejad
Jan 6, 2011·Arthritis Research & Therapy·Andrew Barr, Andrew Keat
Mar 13, 2012·Arthritis Research & Therapy·Fernando Kemta LekpaUNKNOWN Club Rhumatismes et Inflammation
Jun 1, 2008·Biologics : Targets & Therapy·Bernard Combe
Jan 15, 2010·Srpski arhiv za celokupno lekarstvo·Dusan MusturMihailo Ille
May 29, 2012·Clinical Medicine & Research·Yusuf KasiryeRomel J Garcia-Montilla

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.